Mind Medicine Announces Closing Of Public Offering, Underwriters’ Option To Purchase Additional Shares

Mind Medicine Inc., a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, announced the closing of its previously announced underwritten public offering, which raised approximately $259 million. All shares were offered by Mind Medicine. The offering included 21,131,250 common shares, without par value, which includes the exercise in full by the underwriters of their option to purchase an additional 2,756,250 common shares, at a public offering price of $12.25 per common share.

The gross proceeds from this offering were approximately $259 million, before deducting underwriting discounts and commissions and . . .